Benlysta

Reducing disease activity in adults w/ active autoAb +ve SLE receiving standard therapy. Active lupus nephritis in adults in combination w/ background immunosuppressive therapies.

Adult SLE & lupus nephritis 10 mg/kg IV infusion over 1 hr on days 0, 14 & 28 & at 4-wk intervals thereafter. Premed w/ oral antihistamine w/ or w/o antipyretic before infusion.

Hypersensitivity.

Not to be inj as IV push or bolus. Discontinue use if progressive multifocal leukoencephalopathy is confirmed or infusion reaction develops. History of multiple drug allergies or significant hypersensitivity. Not to be initiated in patients w/ active serious infections eg, chronic infections. Not recommended in severe active CNS lupus, HIV, history of or current hepatitis B or C, hypogammaglobulinaemia (IgG <400 mg/dL) or IgA deficiency (IgA <10 mg/dL), history of major organ transplant or hematopoietic stem cell/marrow transplant or renal transplant. Active or latent TB, history of recurrent infection, malignancies & lymphoproliferative disorders. Psychiatric disorders eg, depression, suicidal ideation & behaviour; monitor for new or worsening psychiatric symptoms. Screen for hepatitis B, C & TB prior to therapy. Avoid immunization w/ live vaccines 30 days before & during therapy. Co-administration w/ other B-cell targeted therapy. Women of childbearing potential should use adequate contraception during & at least 4 mth after last dose. Pregnancy & lactation. Not recommended in childn & adolescents w/ active lupus nephritis. Childn <18 yr. Not recommended in elderly >65 yr.

Infections. Hypersensitivity reactions; depression; rash, urticaria; pyrexia, infusion-related systemic reactions.

Not compatible w/ 5% dextrose. Avoid concomitant biologic B-cell targeted therapies.

Immunosuppressants

L04AG04 - belimumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.

B